Evidence map›Paper›PMID 25272020›Full record

ArticlePloS one2014

Adenosine deaminase acting on RNA-1 (ADAR1) inhibits HIV-1 replication in human alveolar macrophages.

Michael D Weiden, Satomi Hoshino, David N Levy, Yonghua Li, Rajnish Kumar, Sean A Burke, Rodney Dawson, Catarina E Hioe, William Borkowsky, William N Rom and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. In-depth investigation of the point mutation pattern of HIV-1.Frontiers in cellular and infection microbiology · 2022
    Article
  6. Molecular Biology and Diversification of Human Retroviruses.Frontiers in virology (Lausanne, Switzerland) · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Michael D WeidenDivision of Pulmonary & Critical Care Medicine, Departments of Medicine and Environmental Medicine, New York University School of Medicine, New York, New York, United States of America.
Satomi HoshinoDivision of Pulmonary & Critical Care Medicine, Departments of Medicine and Environmental Medicine, New York University School of Medicine, New York, New York, United States of America.
David N LevyDepartment of Basic Sciences and Craniofacial Biology, New York University College of Dentistry, New York, New York, United States of America.
Yonghua LiDepartment of Pediatrics, New York University School of Medicine, New York, New York, United States of America.
Rajnish KumarDepartment of Pathology, New York University School of Medicine, New York, New York, United States of America; VA New York Harbor Healthcare System-Manhattan Campus, New York, New York, United States of America.
Sean A BurkeDepartment of Basic Sciences and Craniofacial Biology, New York University College of Dentistry, New York, New York, United States of America.
Rodney DawsonLung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Catarina E HioeDepartment of Pathology, New York University School of Medicine, New York, New York, United States of America; VA New York Harbor Healthcare System-Manhattan Campus, New York, New York, United States of America.
William BorkowskyDepartment of Pediatrics, New York University School of Medicine, New York, New York, United States of America.
William N RomDivision of Pulmonary & Critical Care Medicine, Departments of Medicine and Environmental Medicine, New York University School of Medicine, New York, New York, United States of America.
Yoshihiko HoshinoDivision of Pulmonary & Critical Care Medicine, Departments of Medicine and Environmental Medicine, New York University School of Medicine, New York, New York, United States of America.
New York University · USUniversity of Cape Town · ZAVA NY Harbor Healthcare System · US

Funding

VIROLOGY COREP30AI027742 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DUSTIN, MICHAEL LORAN · 1989 to 2010
$19.4M
HIV/TB INTERACTION IN THE LUNGR01HL057879 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WEIDEN, MICHAEL D. · 1999 to 2008
$3.8M
HOST RESPONSE TO TB AND AIDSR01HL059832 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROM, WILLIAM N · 1997 to 2006
$3.6M
Why Th Cells from HIV+ Don't Respond to HIV AntigensR01AI048371 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HIOE, CATARINA E · 2002 to 2010
$2.6M
HIV-1 Replication Without IntegrationR01AI078783 · NIAID · NEW YORK UNIVERSITY · PI LEVY, DAVID N · 2009 to 2013
$2.1M
HIV activation in secondary pulmonary infectionK24AI080298 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WEIDEN, MICHAEL D. · 2008 to 2013
$868k
HIV-1 Recombination In Natural Target CellsR01AI058876 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEVY, DAVID N · 2004 to 2005
$416k
NHLBI NIH HHS HL57879NHLBI NIH HHS HL59832NHLBI NIH HHS HL93016NHLBI NIH HHS R01 HL057879NHLBI NIH HHS R01 HL059832NIAID NIH HHS AI27742NIAID NIH HHS AI48371NIAID NIH HHS AI58876NIAID NIH HHS AI80298NIAID NIH HHS K24 AI080298NIAID NIH HHS P30 AI027742NIAID NIH HHS R01 AI048371NIAID NIH HHS R01 AI058876NIAID NIH HHS R01 AI078783NIDA NIH HHS DA22612
6 · The paper itself

Abstract

While exploring the effects of aerosol IFN-γ treatment in HIV-1/tuberculosis co-infected patients, we observed A to G mutations in HIV-1 envelope sequences derived from bronchoalveolar lavage (BAL) of aerosol IFN-γ-treated patients and induction of adenosine deaminase acting on RNA 1 (ADAR1) in the BAL cells. IFN-γ induced ADAR1 expression in monocyte-derived macrophages (MDM) but not T cells. ADAR1 siRNA knockdown induced HIV-1 expression in BAL cells of four HIV-1 infected patients on antiretroviral therapy. Similar results were obtained in MDM that were HIV-1 infected in vitro. Over-expression of ADAR1 in transformed macrophages inhibited HIV-1 viral replication but not viral transcription measured by nuclear run-on, suggesting that ADAR1 acts post-transcriptionally. The A to G hyper-mutation pattern observed in ADAR1 over-expressing cells in vitro was similar to that found in the lungs of HIV-1 infected patients treated with aerosol IFN-γ suggesting the model accurately represented alveolar macrophages. Together, these results indicate that ADAR1 restricts HIV-1 replication post-transcriptionally in macrophages harboring HIV-1 provirus. ADAR1 may therefore contribute to viral latency in macrophages.

Indexed as

Virus ReplicationAdenosine DeaminaseAmino Acid SubstitutionBronchoalveolar Lavage FluidGene ExpressionGene Knockdown TechniquesGenotypeHIV-1HIV Envelope Protein gp120HIV InfectionsHumansInterferon-gammaMacrophages, AlveolarMutationPeptide FragmentsProtein IsoformsADAR protein, humanAdenosine DeaminaseHIV Envelope Protein gp120HIV envelope protein gp120 (305-321)Interferon-gammaPeptide FragmentsProtein IsoformsRNA-Binding ProteinsRNA, Small Interfering

Identifiers

PMID25272020
PMCPMC4182706
OpenAlexW2021184083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.